A Safety Risk-Based Extractables and/or Leachables Qualification Strategy for Packaged Drug Products

References

1. 1.↵
   Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Documentation; U.S. Department of Health and Human Services, Food and Drug Administration; Rockville, MD, 1999.
2. 2.↵
   U.S. Pharmacopeial Convention, General Chapter <1664> Assessment of Leachables Associated with Pharmaceutical Packaging/Delivery Systems. In USP 41-NF 36, USP: Rockville, MD, 2018.
3. 3.↵
   1. Jenke D.

   Accounting for Risk When Designing Chemical Safety Assessments for Pharmaceutical Packaging Systems. Eur. Pharm. Rev. 2018, 23 (1), 20, 22, 24.

   OpenUrl
4. 4.↵
   BioPhorum Operations Group. Biophorum Operations Group (BPOG) Best Practices Guide for Evaluating Leachables Risk from Polymeric Single-Use Systems Used in Biopharmaceutical Manufacturing, 2018. https://www.biophorum.com/wp-content/uploads/bp_downloads/Leachables-report-12-April-2017-v3-1.pdf (accessed December 5, 2021).
5. 5.↵
   1. Jenke D.

   Development and Justification of a Risk Evaluation Matrix to Guide Chemical Testing Necessary to Select and Qualify Plastic Components Used in Production Systems for Pharmaceutical Products. PDA J. Pharm. Sci. Technol. 2015, 69 (6), 677–712.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   U.S. Pharmacopeial Convention, General Chapter <1665> Characterization of Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products. In PF46(5), USP: Rockville, MD, 2020.
7. 7.↵
   Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk; U.S. Department of Health and Human Services, Food and Drug Administration; Rockville, MD, 2018.
8. 8.↵
   Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP). Guideline on Plastic Immediate Packaging Materials. CPMP/QWP/4359/03; European Medicines Agency Inspections; London, UK, 2005.
9. 9.↵
   U.S. Pharmacopeial Convention, General Chapter <661.1> Plastic Materials of Construction. In USP43–NF38: Document ID, GUID-560BA7C5-176D-4976-8AB2-A051582B39C7_10_en-US, USP: Rockville, MD, not yet official.
10. 10.↵
    U.S. Pharmacopeial Convention, General Chapter <87> Biological Reactivity Tests, In Vitro. In USP43–NF38, USP: Rockville, MD, 2016, 6514.
11. 11.↵
    U.S. Pharmacopeial Convention, General Chapter <88> Biological Reactivity Tests, In Vivo. In USP43–NF38, USP: Rockville, MD, 2013, 6516.